(Total Views: 455)
Posted On: 01/20/2021 10:13:33 AM
Post# of 149009
Regarding HGEN, Dr Patterson stated their therapeutic would only show acceptable efficacy in 20% of covid-19 infected patients. Don't ask for link, I can't keep up with all the vast numbers of articles and news etc., but I have a good memory. Gotta go, can't find my keys or wallet.
So boards are saying the data is blinded to Humanigen, but endpoint was changed. Did the DSMC just "recommend" changing the endpoint, and Humanigen blindly just said OK. It does result in an endpoint being easier to meet. Someone here said patients on ventilation were excluded in the prior endpoint, but now they added that any patient who advanced to go onto ventilation, would be excluded. That sounds like cheating to me??
Can someone give a review of exclusions we have in our s/c trial? Are patients on ventilation allowed into our trial, seems they would be the hardest to save, and would thus diminish our results?
So boards are saying the data is blinded to Humanigen, but endpoint was changed. Did the DSMC just "recommend" changing the endpoint, and Humanigen blindly just said OK. It does result in an endpoint being easier to meet. Someone here said patients on ventilation were excluded in the prior endpoint, but now they added that any patient who advanced to go onto ventilation, would be excluded. That sounds like cheating to me??
Can someone give a review of exclusions we have in our s/c trial? Are patients on ventilation allowed into our trial, seems they would be the hardest to save, and would thus diminish our results?
(2)
(0)Scroll down for more posts ▼
